Meijer announced today it is launching its new Consumer Drug Take-Back Program by installing secure in-store kiosks designed to help customers safely and properly dispose of unused or expired prescription drugs at no cost. Customers can find the easily identifiable kiosks in the pharmacy area in all 241 Meijer supercenters across the Midwest.
“Meijer is thrilled to be one of the first in our industry to provide a secure and convenient prescription drug take-back program at all stores in the communities we serve,” said Jason Beauch, Vice President of Meijer Pharmacy. “The Meijer Drug Take-Back Program allows our customers to remove the risk of an unforeseen accident occurring with expired or unused medications, while enabling them to properly dispose prescription drugs and reducing the possibility of creating a public health hazard.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8497051-meijer-consumer-drug-take-back-program/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced the winners of its 2016 Health Hero Awards (http://www.webmd.com/healthheroes/what-is-hero), recognizing individuals who are changing the healthcare landscape by meeting a health challenge and giving back to others. This year’s winners are Seth Rogen and Lauren Miller Rogen, Ed Damiano, PhD, Betty Ferrell, RN, PhD and Trisha Prabhu.
On November 3, 2016, an accomplished and inspiring lineup of presenters and performers will gather to honor the winners at the 3rd Annual WebMD Health Hero Awards gala, hosted by Good Morning America co-anchor Robin Roberts. This year’s presenters include David Krumholtz, Adam Savage, and Sarah Wynter, with musical performances by A Great Big World and Naturally 7.
To watch the red carpet arrivals as they happen live from the TimesCenter in New York City, follow WebMD on www.facebook.com/webmd beginning at 6:30 PM ET on November 3, and be sure to follow @WebMD on Instagram, Snapchat and Twitter for updates throughout the night with #HealthHeroes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579756-webmd-2016-health-hero-awards/
Whole You, a Mitsui Chemicals Company dedicated to offering innovative healthcare solutions to help those with sensory and physical mobility challenges experience life more fully, launched its Whole Day campaign video today. The video follows acclaimed photographer Bruce Hall, who has been legally-blind since birth, as he captures a celebration of the senses and movement.
“At Whole You we want nothing less than to change how people understand what it means to be healthy – we develop solutions that enable people to move, see, smell, taste and experience the world more fully than ever before,” said Hiromi Inagaki, chief innovation officer, Whole You. “The video with Bruce is an expression of this vision, a place where sensory or physical mobility challenges don’t hold us back, where we celebrate the senses and freedom of movement to have a deeper appreciation of a life lived beyond limitations.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7704351-whole-you-bruce-hall-campaign/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
Industry leaders attending the first Smart China Expo (SCE 2018) in China’s western city of Chongqing have articulated a new vision for how the world’s digital economy will evolve at the event’s Global Digital Economy Summit, a forum that brought together 650 participants under the theme “New Digital Economy, New Growth Engine.” Speakers projected a future in which Big Data reshapes the way businesses and governments operate, cooperate, and compete.
New forces being unleashed by current innovations threaten to disrupt the existing economic growth models of many industries, as digital information will rise to the same status as land and capital as a key element of productivity. Meanwhile, governments around the world are building “smart infrastructure” as they seek to use technology to upgrade power grids, railways, ports and toll roads, and seek to integrate everything. Big Data technology also helps build “smart cities,” boost consumption, and improve social welfare programs ranging from education to philanthropy to healthcare.
To view the multimedia release go to:
https://www.multivu.com/players/English/8389751-smart-china-expo-sce-2018/
George Freeman MP, the Minister for Life Sciences, will give the keynote address at the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
George Freeman’s keynote address will outline the Government’s aim to develop, assess and adopt new drugs, devices and diagnostics as we move towards 21st century, personalised healthcare.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423951-george-freeman-astellas-debate/
Although the NHS is ranked as one of the institutions that makes people ‘most proud to be British’1, a new poll commissioned by Astellas Pharma Europe Ltd, highlights that 91% of people feel that the health service is in need of change2. In particular, shorter waiting times (36% of respondents) and improved access to medicines (30%) rank most highly as the areas in need of greatest reform.
With only 1 in 4 of respondents agreeing that the Government currently spends enough on health, the survey reveals that those polled would be willing to accept an average charge of £10 for a missed GP appointment in order to improve service levels. The people polled also said they would be willing to pay an average of £170 per year in additional income tax for healthcare funding – which could result in approximately £5 billion in additional tax revenue for the Treasury3. In addition to these charges, 39% of those polled would be willing to accept an additional charge if it meant quicker access to healthcare services and 44% of those polled would be willing to accept additional charges if it meant access to newer and potentially more effective medicines.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7753151-astellas-survey-public-support-nhs-concern/
